<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00745108</url>
  </required_header>
  <id_info>
    <org_study_id>P06470</org_study_id>
    <secondary_id>32972</secondary_id>
    <nct_id>NCT00745108</nct_id>
  </id_info>
  <brief_title>Tibolone Endometrium Study (Study 32972)(P06470)</brief_title>
  <acronym>THEBES</acronym>
  <official_title>A Multinational, Multicenter, Randomized, Double-blind, Parallel Group, Active Controlled, Comparative Trial, to Assess the Endometrial Histological Profile Following Treatment With Tibolone (Org OD14) Versus Conjugated Estrogen (CE) Plus Medroxyprogesterone Acetate (MPA) in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tibolone has been registered for the treatment of climacteric symptoms and for the prevention
      of postmenopausal osteoporosis. This is a 2-year study to further confirm the endometrial
      safety of tibolone in comparison with CE/MPA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2001</start_date>
  <completion_date type="Actual">July 21, 2005</completion_date>
  <primary_completion_date type="Actual">July 21, 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endometrial biopsy and histological examination</measure>
    <time_frame>At 1 year and 2 year.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Double-layer endometrial thickness by transvaginal ultrasonography (TVUS), vaginal bleeding from a Bleeding Episode Log.</measure>
    <time_frame>TVUS: at 1 year and 2 year; Vaginal bleeding: daily recording</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Postmenopausal Women</condition>
  <arm_group>
    <arm_group_label>Tibolone 1.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tibolone 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CE/MPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tibolone</intervention_name>
    <description>oral 1.25 mg tablet, once daily, for 2 years</description>
    <arm_group_label>Tibolone 1.25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tibolone 2.5 mg</intervention_name>
    <description>oral 2.5 mg tablet, once daily, for 2 years</description>
    <arm_group_label>Tibolone 2.5 mg</arm_group_label>
    <other_name>Livial</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CE/MPA</intervention_name>
    <description>oral, 0.625 mg tablet conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate tablet placed together in a single capsule, once daily, for 2 years</description>
    <arm_group_label>CE/MPA</arm_group_label>
    <other_name>Premarin</other_name>
    <other_name>Provera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy postmenopausal women, 45 to 65 years of age with an intact uterus. Women must
             have been postmenopausal for less than 15 years, have an atrophic or inactive
             endometrium, and a body mass index of 18 - 32 kg/ m2 (inclusive).

        Exclusion Criteria:

          -  Final diagnosis of the endometrial biopsy as 'no tissue' or 'tissue insufficient for
             diagnosis'.

          -  Double layer endometrial thickness &gt; 6 mm as assessed by transvaginal ultrasonography
             (TVUS).

          -  Any previous or current unopposed estrogen administration or tamoxifen citrate.

          -  Any unexplained vaginal bleeding following the menopause.

          -  Women with abnormal Pap smear test results (PAP IIb and higher)

          -  Previous use of raloxifene hydrochloride for longer than one month.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2008</study_first_submitted>
  <study_first_submitted_qc>September 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Tibolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

